Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
Unknown
This study is intended to show whether inhaled chemotherapy can be added to a standard IV chemotherapy regime, to investigate the additional toxicities and to show initial evidence of efficacy of the combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2006
Locations: Yale University Cancer Center, New Haven, Connecticut +5 locations
Conditions: NSCLC